We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

97 hedge funds and large institutions have $1.14B invested in Aclaris Therapeutics in 2021 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

479% more capital invested

Capital invested by funds: $198M → $1.14B (+$947M)

400% more funds holding in top 10

Funds holding in top 10: 3 → 15 (+12)

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

52% more call options, than puts

Call options by funds: $6.4M | Put options by funds: $4.21M

23% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 26

18% more funds holding

Funds holding: 82 → 97 (+15)

13.27% more ownership

Funds ownership: 74.4% → 87.68% (+13%)

Holders
97
Holders Change
+15
Holders Change %
+18.29%
% of All Funds
1.7%
Holding in Top 10
15
Holding in Top 10 Change
+12
Holding in Top 10 Change %
+400%
% of All Funds
0.26%
New
33
Increased
32
Reduced
26
Closed
17
Calls
$6.4M
Puts
$4.21M
Net Calls
+$2.19M
Net Calls Change
-$645K

Top Buyers

1
FCMI
Foresite Capital Management IV
California
+$47.9M
2
CAM
Cormorant Asset Management
Massachusetts
+$39.1M
3
VA
VR Adviser
New York
+$34.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.3M
5
Citadel Advisors
Citadel Advisors
Florida
+$25.1M

Top Sellers

1
ECM
Endurant Capital Management
California
-$13.1M
2
SI
Sofinnova Investments
California
-$12.4M
3
EC
EcoR1 Capital
California
-$9.77M
4
SB
Samsara BioCapital
California
-$6.65M
5
CC
Commodore Capital
New York
-$6.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
76
Telemetry Investments
New York
$252K -$720K -36,800 -79%
Morgan Stanley
77
Morgan Stanley
New York
$224K -$182K -9,329 -51%
Squarepoint
78
Squarepoint
New York
$215K +$167K +8,537 New
Victory Capital Management
79
Victory Capital Management
Texas
$204K +$158K +8,078 New
UBS Group
80
UBS Group
Switzerland
$160K +$99K +5,060 +387%
Citigroup
81
Citigroup
New York
$156K -$710K -36,302 -85%
DWA
82
Dorsey Wright & Associates
California
$154K +$68.6K +3,510 +135%
Royal Bank of Canada
83
Royal Bank of Canada
Ontario, Canada
$89K +$31.7K +1,621 +86%
Osaic Holdings
84
Osaic Holdings
Arizona
$73K -$21.6K -1,105 -28%
CG
85
Cutler Group
California
$73K -$13.7K -700 -19%
MS
86
Maven Securities
Jersey
$66K +$50.9K +2,605 New
OSAM
87
O'Shaughnessy Asset Management
Connecticut
$43K +$743 +38 +2%
Wells Fargo
88
Wells Fargo
California
$35K -$617K -31,546 -96%
PA
89
Parallel Advisors
California
$30K -$7.82K -400 -25%
PAM
90
Panagora Asset Management
Massachusetts
$20K – – –
TRCT
91
Tower Research Capital (TRC)
New York
$17K +$8.17K +418 +153%
Northwestern Mutual Wealth Management
92
Northwestern Mutual Wealth Management
Wisconsin
$13K – – –
Federated Hermes
93
Federated Hermes
Pennsylvania
$7K -$20.4K -1,043 -78%
TC
94
Truvestments Capital
Florida
$4K +$2.93K +150 New
HI
95
Harbour Investments
Wisconsin
$3K +$1.96K +100 New
JP Morgan Chase
96
JP Morgan Chase
New York
$1K -$313 -16 -43%
SI
97
Sofinnova Investments
California
– -$12.4M -1,911,573 Closed
EC
98
EcoR1 Capital
California
– -$9.77M -1,509,812 Closed
OCA
99
Octagon Capital Advisors
New York
– -$2.27M -350,000 Closed
SFM
100
Sphera Funds Management
Israel
– -$971K -150,000 Closed
1 2 3
4
5

ACRS Hedge Fund Activity: Q1 2021 in Review

97 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2021, worth a combined $1.14B — up 479% from $198M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ACRS positions and 17 closed out — a net gain of 16 holders — while 32 added to existing stakes and 26 trimmed.

The largest buyer was Foresite Capital Management IV, adding an estimated $47.9M. The largest seller was Endurant Capital Management, cutting an estimated $13.1M.

  • 97 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2021, up from 82 in Q4 2020.
  • Funds reported $1.14B of Aclaris Therapeutics stock for Q1 2021, up 479% quarter-over-quarter.
  • 33 funds opened new Aclaris Therapeutics positions in Q1 2021 and 17 closed out, a net change of +16 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2021 was Foresite Capital Management IV, an estimated $47.9M added.
  • The largest Aclaris Therapeutics seller in Q1 2021 was Endurant Capital Management, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2021.